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A b s t r a c t
Background: Clinical outcomes of patients with ST-segment elevation myocardial infarction (STEMI) disqualified from an invasive
strategy (InvS) are poorly understood.
Aim: To investigate the short-term result of a conservative strategy (ConS) in a real-life population of patients with STEMI.
Material and methods: 1031 patients with STEMI were retrospectively analyzed. Of these, 194 (18.8%) patients were initially
qualified to the ConS. For the remaining 837 (81.2%) patients the InvS was applied.
Results: The most frequent reasons for disqualification from an InvS in STEMI patients were the duration of ischemia > 12 h
(81.4%), aborted STEMI (9.8%) and anticipated transportation time > 2 h (3.1%). On admission, in the group of InvS, cardiogenic shock
was noted in 45 (5.4%) patients. Death within 30 days was more frequently observed in STEMI patients who underwent ConS vs.
InvS (13.9% vs. 9.0%, p = 0.037). During initial hospitalization 22 (11.3%) patients who underwent ConS and 34 (4.1%, p < 0.001) with
InvS developed symptoms of heart failure (Killip class 2-4). Age (OR 1.07 per year, 95% CI 1.04-1.11, p < 0.0001) and conservative
strategy (OR 1.55, 95% CI 0.73-4.86, p = 0.035) were the independent predictors of death within 30 days. Moreover, in patients with
InvS cardiogenic shock on admission (OR 52.4, 95% CI 18.7-134.1, p < 0.0001) and in patients with ConS heart failure during
hospitalization (OR 10.8, 95% CI 3.2-36.7, p = 0.0002) independently influenced the 30-day mortality (c-statistics 0.83). 
Conclusions: Duration of ischemia of more than 12 h was the main reason for disqualification from InvS. Applied ConS was
associated with higher 30-day mortality when compared to InvS. The symptoms of heart failure were an independent predictor of
death within 30 days in patients with ConS.
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S t r e s z c z e n i e
Wstęp: Wyniki leczenia pacjentów z zawałem serca z uniesieniem odcinka ST (STEMI) niezakwalifikowanych do strategii inwazyjnej
(invasive strategy, InvS) są słabo poznane.
Cel: Ocena bezpośredniego wyniku klinicznego strategii zachowawczej (conservative strategy, ConS) zastosowanej w grupie kolej -
nych pacjentów ze STEMI niezakwalifikowanych do leczenia inwazyjnego.
Materiał i metody: Retrospektywnie przeanalizowano dane 1031 pacjentów ze STEMI leczonych zgodnie z obowiązującymi wytycz -
nymi. Spośród tej grupy 194 (18,8%) chorych zostało pierwotnie zakwalifikowanych do ConS, pozostałych 837 (81,2%) pod-
dano InvS.
Wyniki: Głównymi czynnikami wykluczającymi z InvS w grupie STEMI były: czas niedokrwienia > 12 godz. (81,4%), ustąpienie 
bólu i zmian w EKG (9,8%) i przewidywany czas transportu > 2 godz. (3,1%). Przy przyjęciu 45 (5,4%) pacjentów poddanych InvS 
miało objawy wstrząsu kardiogennego. Śmiertelność 30-dniowa wśród pacjentów STEMI w grupach InvS i ConS wyniosła 
odpowiednio 9,0% i 13,9% (p = 0,037). Podczas pierwotnej hospitalizacji u 22 (11,3%) pacjentów poddanych ConS i 34 (4,1%, p < 0,001)
poddanych InvS pojawiły się objawy niewydolności serca (klasa 2.–4. wg Killipa). Wiek (OR 1,07 na rok, 95% CI 1,04–1,11, p < 0,0001)
i strategia zachowawcza (OR 1,55, 95% CI 0,73–4,86, p = 0,035) były niezależnymi czynnikami wystąpienia zgonu do 30. dnia w całej
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Introduction
Acute coronary syndrome (ACS) is the most life-
threatening clinical manifestations of ischemic heart
disease. Accurate and immediate diagnosis, individual risk
stratification based on clinical situation and adequate
therapy implemented in individual patient without time
delays are the key points for proper and satisfactory short-
and long-term results of ACS treatment [1, 2].
The whole spectrum of ACS, based on ST-T interval
morphology, is divided into two, patophysiologically
different categories: ST-segment elevation myocardial
infarction (STEMI) [3] and non-ST-segment elevation acute
coronary syndrome (NSTACS) [4]. Clinical and thera peutical
approach in those two states is also different.
Primary percutaneous coronary intervention (pPCI) is
the most effective way of coronary flow restoration in
STEMI patients [5], however, it requires advanced logistics
and the regional coordination of health and medical care
providers to reduce delay in invasive treatment, which is
directly correlated with the final result of such
a management strategy [6, 7]. Unfortunately not all STEMI
patients receive the mechanical reperfusion therapy
needed, mainly due to the elapse of a long period from the
onset of ACS symptoms. Meanwhile, results of conservative
therapy with pharmacological treatment only in STEMI
patients initially disqualified from invasive treatment still
remain unclear and poorly understood.
We sought to investigate both the reasons for
disqualification from mechanical reperfusion therapy, as
well as early, in-hospital and 30-day mortality in a group
of consecutive, unselected STEMI patients primary
qualified to receive conservative treatment. We also
compared those results with STEMI patients treated
invasively at the same time in our department. 
Material and methods
Studied group
For the period of time from 1st January to 31st December
2005, physicians from 20 hospitals in Krakow and
surrounding towns and emergency ambulance units
submitted 1604 patients with ACS for coronary intervention
to the duty doctor of the John Paul II Hospital in Krakow.
This group consisted of 561 (35%) NSTACS and 1043 (65%)
STEMI patients. Qualification for invasive treatment of
myocardial infarction was performed in accordance with
the current European Society of Cardiology guidelines on
STEMI [8] and NSTEMI [9] management, approved by the
Polish Cardiac Society. Patients with persistent ST-segment
elevation or newly diagnosed left bundle branch block
(LBBB) were treated with mechanical reperfusion therapy
if duration of myocardial ischemia (time from chest pain
onset) was less than 12 h. In patients with cardiogenic
shock the time windows were longer, up to 18 h from the
shock onset and up to 36 h from the chest pain onset. 
During the first telephone contact between referring
physician and consulting cardiologist, the decision about
following therapy in each individual case of STEMI was
made. Disqualification from pPCI was termed conservative
strategy (ConS), and in those cases pharmacotherapy was
used. Reversely, a decision for immediate interventional
treatment was termed invasive strategy (InvS).
Based on the above mentioned criteria out of all the
1043 STEMI cases submitted to our department, 837 pa -
tients were qualified to receive interventional treatment,
and the remaining 206 patients were to receive
conservative therapy alone. After an assessment of all the
consultation forms for the year 2005, we asked all
collaborating local departments for permission to access
the medical records of those who were treated
conservatively in those wards. Out of 206 patients with
STEMI qualified to ConS, we were able to assess 194
(94.2%) cases. Finally, medical records and clinical data
from collaborating departments (194 patients) and the
catheterization laboratory of our hospital (837 patients)
were collected and analyzed. An evaluation of in-hospital
stay and a 30-day follow-up in 1031 cases of STEMI was
conducted. The 30-day mortality rate was estimated on
the basis of data received from Lesser Poland Voivodal
Registry of Citizens. The study protocol was approved by
the Ethical Committee of the Jagiellonian University
Medical College.
Clinical observation
The primary end-point in this study was death within
a 30-day follow-up. Secondary end-points in our
retrospective observation were: cardiogenic shock at the
time of invasive cardiology consultation, symptoms of heart
failure (Killip class 2-4) during in-hospital period, and
delayed referral for coronary angiography or planned
grupie. Ponadto w grupie pacjentów poddanych InvS objawy wstrząsu kardiogennego przy przyjęciu (OR 52,4, 95% CI 18,7–134,1, 
p < 0,0001), a w grupie pacjentów poddanych ConS objawy niewydolności serca podczas hospitalizacji (OR 10,8, 95% CI 3,2–36,7,
p = 0,0002) niezależnie determinowały 30-dniową śmiertelność (c-statystyka 0.83). 
Wnioski: Najczęstszą przyczyną niezakwalifikowania chorych ze STEMI od InvS było przekroczenie czasu 12 godz. od początku
bólu. Zastosowana ConS była związana z wyższą 30-dniową śmiertelnością w grupie pacjentów ze STEMI. Wśród chorych poddanych
ConS wystąpienie objawów niewydolności serca niezależnie determinowało 30-dniową śmiertelność.
Słowa kluczowe: ostry zawał mięśnia sercowego z uniesieniem odcinka ST, strategia zachowawcza, przezskórna interwencja
wieńcowa
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invasive diagnostics of coronary arteries after primary
hospitalization. 
Statistical analysis 
Statistical analyses were performed with Statistica
Version 6 (StatSoft, Inc.) software. Continuous variables were
presented as the mean value ± standard deviation (SD) and
analyzed using the t-Student test. Categorical variables were
expressed as absolute values, percentages or both, and were
compared by means of chi-square or Fisher test.
Multivariable logistic analysis was performed to obtain
independent predictors of the 30-day mortality. The model
included independent variables, such as: applied treatment
strategy, age, gender, time from the onset of chest pain to
the moment of invasive cardiology consultation, diabetes
mellitus, hypertension, previous myocardial infarction,
symptoms of cardiogenic shock at the time of invasive
cardiology consultation, heart failure symptoms after the
invasive cardiology consultation, pharmacotherapy during
the in-hospital treatment and the referral for delayed
coronary angiography. A c-statistic was calculated to evaluate
the discrimination model. A p value less than 0.05 was
considered statistically significant.
Results
Study groups characteristics
The baseline characteristics of STEMI patients in InvS
and ConS groups is shown in table 1. There were no
significant differences between both groups with regard
to age, gender, arterial hypertension, dyslipidemia and
smoking. Subjects with STEMI from ConS more likely had
a history of previous myocardial infarction (p < 0.0001) and
a history of diabetes (p < 0.0001), less likely underwent
PCI before the analyzed event (p = 0.049) and manifested
pulmonary congestion at the time of invasive cardiology
consultation (p = 0.0001), in comparison to subjects from
the InvS group. The time of ischemia in the InvS group was 
4.6 ±5.0 h, while in over 80% of patients from the ConS
group it exceeded 12 h. All subjects with STEMI and
cardiogenic shock were qualified to InvS and composed
5.4% of the group (tab. 1).
The most frequent reasons for disqualification (tab. 2)
from an InvS in STEMI patients were the time of ischemia
InvS ConS p
Age (mean ±SD) [years] 62.8 ±11.5 64.6 ±12.9 NS
Male gender [% (n/N)] 70.3 (588/837) 69.1 (134/194) NS
Cardiovascular risk factors [% (n/N)]
hypertension 72.5 (607/837) 72.7 (141/194) NS
diabetes 16.1 (135/837) 34.0 (66/194) < 0.0001
dyslipidemia 33.5 (280/837) 36.1 (70/194) NS
smoking 41.5 (347/837) 45.9 (89/194) NS
Previous PCI [% (n/N)] 3.8 (32/837) 0.1 (2/194) 0.049
Previous CABG [% (n/N)] 1.6 (13/837) 0 NS
Previous MI [% (n/N)] 15.2 (127/837) 28.9 (56/194) < 0.0001
Killip class at the time of consultation [% (n/N)]
3 10.5 (88/837) 1.5 (3/194) 0.0001
4 5.4 (45/837) 0 –
Table 1. Baseline characteristics
Tabela 1. Charakterystyka pacjentów
InvS – invasive strategy, ConS – conservative strategy, PCI – percutaneous coronary intervention, CABG – coronary artery bypass surgery, 
MI – myocardial infarction
InvS – strategia inwazyjna, ConS – strategia zachowawcza, PCI – przezskórna interwencja wieńcowa, CABG – pomostowanie aortalno-wieńcowe, 
MI – zawał serca
Criterion
Duration of ischemia > 12 h [% (n/N)] 81.4 (158/194)
Aborted myocardial infarction (all patients with 9.8 (19/194)
time of ischemia less than 12 h) [% (n/N)]
Anticipated transportation time > 2 h [% (n/N)] 3.1 (6/194)
No consent for invasive treatment 2.6 (5/194)
[% (n/N)]
No arterial access [% (n/N)] 0.5 (1/194)
Cardiac arrest with neurological signs of CNS 1.6 (3/194)
damage [% (n/N)]
Unknown reason [% (n/N)] 1.0 (2/194)
Table 2. Criteria of qualification to conservative
strategy
Tabela 2. Kryteria kwalifikacji do strategii inwazyjnej
CNS – central nervous system
CNS – ośrodkowy układ nerwowy
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> 12 h (81.4%). Rarely was the reason for such a decision
aborted STEMI (9.8%) and anticipated transportation time
> 2 h (3.1%, 2 patients received thrombolytic therapy).
Three (1.6%) patients were excluded from InvS due to
sudden cardiac arrest with a subsequent dysfunction of
the central nervous system present during the neurological
examination.
Treatment
Patients qualified for InvS significantly more often
received a tienopiridine derivative antiplatelet drug (93.6%
vs. 34.6%, p < 0.0001) in comparison with the ConS group
(tab. 3). Platelet GP IIb/IIIa receptor inhibitor was used only
in individuals treated with PCI, and 145 subjects from this
group received abciximab. Also heparin was more widely
used in patients qualified for InvS than ConS (99.7% vs.
86.5%, p < 0.0001). 
Primary coronary angioplasty was performed in 90.7%
(759/837) subjects from the InvS group, 1.7% (14/837)
underwent coronary artery bypass graft surgery, and the
remaining 64 (7.6%) were treated with pharmacotherapy
after coronary angiography. In 1.4% (12/837) of cases from
the InvS group who underwent pPCI, a drug eluted stent
was used during the procedure.
Treatment strategy and clinical results.
Out of the patients treated with ConS in district and
regional hospitals 21 (10.8%) patients died, 44 (22.7%) were
referred directly to the local catheterization laboratory for
delayed coronary angiography and/or interventional
treatment (missing data) and 129 (66.9%) were discharged
home, out of whom 20 (10.3%) had a planned hospitalization
appointment for elective coronary angiography within 
3 months from the discharge date (tab. 4). In the group of
44 subjects primary qualified to ConS, and transferred for
delayed invasive diagnostics to a catheterization laboratory,
4 patients died due to the development of heart failure.
Following discharge from the hospital, but before the 
30 days of follow-up, additional 2 deaths were reported.
Overall the in-hospital mortality rate in the ConS group was
12.9%, and a 30-day mortality 13.9% (fig. 1).
In STEMI patients qualified to receive InvS, 55 (6.6%)
cases of in-hospital death were noted, 35 of those due to
the rapid development of cardiogenic shock. 517 (61.8%)
patients from InvS after initial invasive treatment were
transferred to other wards and department in local and
district hospitals for subsequent treatment and continuation
of a guideline-based pharmacotherapy. Two hundred sixty
fife (31.6%) InvS subjects were directly discharged home in
good condition when reconvalescence had been completed
(tab. 4). Out of 517 patients transferred to other hospitals,
18 patients died from the group (517 patients). Between
discharge home and within the 30-days of follow-up,
another 2 deaths were reported. In-hospital mortality was
estimated and reached 8.7%, whereas 30-days mortality
was at the level of 9.0% and was significantly lower 
(p = 0.037) than that observed in the ConS group (fig. 1).
The mean duration of in-hospital stay completed with
home discharge in the ConS group was significantly longer
than it was in the case in the InvS group (mean 10.7 vs. 
4.7 days, p < 0.0001) (tab. 4). Symptoms and signs of heart
failure in Kilip class 2-4 developed in 22 (11.3%) patients
from ConS and in 34 (4.1%) from InvS.
Advanced age and conservative strategy were the
independent predictors of the risk of death within 30 days
following discharge in all subjects with myocardial
infarction (tab. 4). Moreover, statistical interactions between
the applied treatment strategy and symptoms of
cardiogenic shock at the time of consultation, and also
between implemented management and the development
of heart failure already after consultation. 
In the InvS group symptoms of cardiogenic shock on
admission and in ConS symptoms signs of heart failure
during hospitalization period were independently correlated
with the 30-day mortality rate in our observation 
(c-statistics 0.83). 
Discussion
Our study demonstrates that application of guidelines
on the management of STEMI current in year 2005 was
associated with a higher 30-day mortality in patients
treated conservatively without initial invasive coronary
InvS ConS p
Acetylosalicylic acid [% (n/N)] 98.7 (820/831) 98.4 (188/191) NS
Clopidogrel/ticlopidine [% (n/N)] 93.6 (773/826) 34.6 (66/191) < 0.0001
Abciximab [% (n/N)] 18.1 (145/830) 0 –
Eptifibatide [% (n/N)] 0 0 –
Unfractioned heparin [% (n/N)] 93.1 (770/827) 77.6 (149/192) NS
Low molecular weight heparin [% (n/N)] 6.6 (55/830) 8.9 (17/191) NS
Table 3. Antiplatelet and anticoagulant therapy
Tabela 3. Terapia przeciwpłytkowa i przeciwzakrzepowa
InvS – invasive strategy, ConS – conservative strategy
InvS – strategia inwazyjna, ConS – strategia zachowawcza
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Fig. 1. 30-day mortality rate
InvS – invasive strategy, ConS – conservative strategy 
Ryc. 1. Śmiertelność 30-dniowa
InvS – strategia inwazyjna, ConS – strategia zachowawcza
InvS
35/837
ConS
[%
]
17/194
55/837 73/837 75/837 21/194 25/194 27/194
invasive after transfer to after regional  after transfer to after discharge
cardiology non-invasive ward discharge hospitals invasive and before
unit and before 30 days cardiology unit 30 days
all patients patients with cardiogenic shock at the time of qualification patients with heart failure after qualification (Killip class 2-4)
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InvS Hospitalization duration [day, mean ±SD] 4.7 ±3.1
N = 837 Symptoms of heart failure (KK 2-4), n (%) 34 (4.1)
Transfer to other ward, n (%) 517 (61.8)
Discharge home, n (%) 265 (31.6)
In-hospital mortality, n (%) 73 (8.7)
30-day mortality, n (%) 75 (9.0)
ConS Hospitalization duration [day, mean ±SD] 10.7 ±7.9
N = 194 Symptoms of heart failure (Killip class 2-4), n (%) 22 (11.3)
Transfer to catheterization laboratory, n (%) 44 (22.7)
Discharge home, n (%) 129 (66.5)
including those patients with planned coronary angiography within 3 months from discharge date 20 (10.3)
In-hospital mortality 25 (12.9)
30-day mortality 27 (13.9)
Table 4. Thirty-day clinical outcome
Tabela 4. Obserwacja 30-dniowa
InvS – invasive strategy, ConS – conservative strategy
InvS – strategia inwazyjna, ConS – strategia zachowawcza
approach. The main aim of our study was not only an
evaluation of early clinical results but also, and more
importantly, a selection of potential predictors and risk
factors of unfavorable clinical outcomes in STEMI patients. 
In the studied STEMI group qualified to ConS in over
80% of cases duration of myocardial ischemia was greater
than 12 h. Although mechanical reperfusion therapy of
STEMI patients before 12 h of chest pain duration is
a widely accepted and approved standard of care [1, 9], the
management of those patients after that time line is rather
unclear and questionable. Joint consensus of experts and
medical boards, not supported by large randomized clinical
trials, indicates potential benefits from coronary
intervention after 12 h from the chest pain onset and it may
14
12
10
8
6
4
2
* p = 0.075, ** p = 0.037 
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Independent variable 30-day mortality
OR 95% CI p
Interaction of symptoms of cardiogenic shock at the time of consultation with applied treatment < 0.0001
strategy
InvS (shock vs. non-shock) 52.4 18.7-134.1
Age (per year) 1.07 1.04-1.11 < 0.0001
Interaction of symptoms of heart failure (Killip class 2-4) after consultation with applied treatment 0.0002
strategy
InvS (HF vs. non-HF) 1.34 0.49-3.38
ConS (HF vs. non-HF) 10.8 3.2-36.7
Treatment strategy (ConS vs. InvS) 1.55 0.73-4.86 0.035
GP IIb/IIIa receptor antagonist (Y/N) 0.86 0.68-1.28 0.19
Duration of ischemia (per hour) 1.04 0.98-1.16 0.21
Clopidogrel/ticlopidine (Y/N) 0.93 0.64-1.45 0.27
Anterior wall myocardial infarction (Y/N) 1.81 1.15-2.88 0.28
Diabetes mellitus (Y/N) 1.44 0.57-3.64 0.44
Gender (M vs. F) 0.92 0.39-2.16 0.84
Previous myocardial infarction (Y/N) 1.01 0.38-2.67 0.98
Table 5. Independent predictors of death within 30 days 
Tabela 5. Niezależne czynniki ryzyka wystąpienia zgonu w obserwacji 30-dniowej
c-statistics 0.83
InvS – invasive strategy, ConS – conservative strategy, shock – cardiogenic shock, HF – heart failure, Y/N – yes/no, M – male, F – female 
InvS – strategia inwazyjna, ConS – strategia zachowawcza, shock – szok kardiogenny, HF – niewydolność serca, Y/N – tak/nie, M – mężczyzna, F – kobieta
be recommended in cases of persistent clinical symptoms
and/or signs in electrocardiogram indicating ongoing
myocardial ischemia [1]. Additionally, currently there is
a registry [10] and a prospective randomized clinical trial
[11] addressed to asymptomatic STEMI patients after the
12th h from the onset of this condition. Accordingly, PCI in
STEMI patients between the 12th and 48th h from the onset
of chest pain is related to a significant reduction of the
myocardial infarction area, measured in a single photon
emission computed tomography between the 5th and 10th
day (13% vs. 8%, p < 0.001). However, those results though
visible in medical imaging did not improve clinical
outcomes. Those observations have apparently been
proved by other studies, like the sub-analysis of the OAT
study [12]. It was shown that reperfusion of the occluded
infarct-related artery in asymptomatic STEMI patients
between the 24 and 72 hrs from the onset of myocardial
ischemia symptoms was related to no clinical benefits in
comparison to standard conservative therapy. 
Our study is another one that reports a significantly
increased mortality rate in STEMI patients treated
conservatively. It is worth noting that the observed 30-days
mortality rate in the ConS group with no cardiogenic shock
at the time of consultation, and qualification to one of two
possible strategies of management, was close to 14%. That
indicates that the development of heart failure already after
primary consultation and therapeutic way assignment still
remains an unresolved problem in the STEMI population.
Immediate diagnosis establishment, appropriate therapy
introduction with no time delays and reconsideration of the
invasive strategy appear to be correct, which may improve
the clinical outcomes in ConS STEMI patients. Our
observations based on the collected material indicates that
only about 1/5 of STEMI patients primary enrolled in the
ConS group underwent early invasive coronary angiography,
and another 10% were referred to a catheterization
laboratory within 3 months of discharge home. Observations
from recent years show that an increased number of
catheterization laboratories and the greater availability of
invasive cardiology is connected with improved treatment
outcomes in STEMI patients, what has its reflection in up-
to-date guidelines for the management of STEMI [1].
It seems that if in STEMI patient treated in conservative
way, mainly due to excessive duration of myocardial
ischemia, signs and symptoms of heart failure set in, it is
always worth re-consulting his treatment options and re-
considering an invasive way for the management of that
state. 
Study limitations
Our study has several limitations. First, it is
a retrospective study of clinical consequences of risk
stratification and a decision making algorithm used in the
management of STEMI patients in 2005. Second, despite
our extensive efforts, we were not able to collect data of
6% of patients in the conservative treatment group. Third,
Jarosław Zalewski et al.  Conservative strategy in STEMI patients
due to the different and heterogenous description criteria
of ischemia recurrence and reinfarction used in many
centers and the lack of an objective tool for those states
with regard to a retrospective clarification, our study did
not analyze either recurrent myocardial ischemia nor
reinfarction in the conservative strategy group. Finally, we
did not perform any kind of coronary angiography analysis
in cases from the conservative strategy group referred to
delayed coronary angiography in different catheterization
laboratories, due to an inability to collect a sufficient
amount of angiographic data, though in our opinion such
an analysis could provide additional, interesting and
important information and insight into the discussed
problem. 
Conclusions
The main reason for disqualification from invasive
treatment in the presented group of STEMI patients was
duration of myocardial ischemia exceeding 12 h. Applied
conservative strategy in this group of patients was
independently associated with higher 30-day mortality rate
when compared to invasive treatment. The symptoms of
heart failure were an independent predictor of death within
30 days in patients qualified to conservative strategy.
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